Heterobicycloaryl RORC2 Inhibitors Modulating IL-17 Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune and inflammatory disorders, such as psoriasis, often have toxic adverse effects and insufficient efficacy, highlighting a need for improved therapeutic agents that can effectively modulate retinoid-related orphan receptor gamma (RORγ) activity.
Innovation Solution
Development of compounds represented by Formula II and their pharmaceutical compositions, which inhibit RORγ activity and reduce IL-17 levels, providing therapeutic benefits for various medical disorders including psoriasis, rheumatoid arthritis, and other immune and inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressive drugs and traditional therapies are used to treat immune and inflammatory disorders, then some therapeutic effect is achieved, but toxic adverse effects occur and efficacy is insufficient for many patients
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of RORγ modulators through various substituent groups (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10) to optimize the balance between therapeutic efficacy and toxicity. By systematically varying molecular parameters such as substituent types, positions, and configurations, the invention aims to achieve selective RORγ modulation that maintains effectiveness while reducing harmful side effects associated with conventional immunosuppressants
2Ease of operation
If traditional therapies for psoriasis are administered, then some symptom relief is provided, but the treatments often have toxic adverse effects and do not provide satisfactory results for all patients
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular characteristics tailored to target RORγ selectively. The structured approach with defined substituent positions (R1-R10) allows optimization of local molecular interactions with the RORγ ligand-binding domain, enhancing therapeutic efficacy for psoriasis and other immune disorders while maintaining ease of administration through oral or topical delivery of precisely engineered molecules
Data Source
AI summary
The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.